Progress in the evaluation of CDK inhibitors as anti-tumor agents

Drug Discovery Today

Volumn 13, Issue 19-20, 2008, Pages 875-881

  McInnes, Campbell ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN GROOVE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; JNJ 7706621; MYC PROTEIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; RO 3306; ROSCOVITINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CELL CYCLE REGULATION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; IC 50; LOADING DRUG DOSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RASH; RETINOBLASTOMA; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG EVALUATION, PRECLINICAL; HUMANS; PROTEIN KINASE INHIBITORS;

EID: 52049097040     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.06.012     Document Type: Review

References (48)

1. Balter M., and Vogel G. Nobel prize in physiology or medicine. Cycling toward Stockholm. Science 294 (2001) 502-503
2. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005) 630-641
3. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006) 1770-1783
4. Hu D., et al. CDK11(p58) is required for the maintenance of sister chromatid cohesion. J. Cell Sci. 120 Pt 14 (2007) 2424-2434
5. Carrano A.C., et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1 (1999) 193-199
6. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 21 (2002) 6170-6174
7. Ma T., et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 14 (2000) 2298-2313
8. Chen Y.N., et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4325-4329
9. Ubersax J.A., et al. Targets of the cyclin-dependent kinase Cdk1. Nature 425 (2003) 859-864
10. Loyer P., et al. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal 17 (2005) 1033-1051
11. Malumbres M., et al. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol. Sci. 29 (2008) 16-21
12. Ortega S., et al. Cyclin-dependant kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35 (2003) 25
13. Berthet C., et al. Cdk2 knockout mice are viable. Curr. Biol. 13 (2003) 1775-1785
14. Malumbres M., et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118 (2004) 493-504
15. Santamaria D., et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (2007) 811-815
16. Toogood P.L., et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J. Med. Chem. 48 (2005) 2388-2406
17. Landis M.W., et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9 (2006) 13-22
18. Yu Q., et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9 (2006) 23-32
19. Baughn L.B., et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66 (2006) 7661-7667
20. Fry D.W., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Therap. 3 (2004) 1427-1438
21. Marzec M., et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108 (2006) 1744-1750
22. www.clinicaltrials.gov/ct2/results?term=pd0332991
23. Vassilev L.T., et al. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 10660-10665
24. Vassilev L.T. Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1. Cell Cycle 5 (2006) 2555-2556
25. Chen S., et al. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2134-2138
26. Goga A., et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13 (2007) 820-827
27. Fischer P.M., and Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin. Investig. Drugs 14 (2005) 457-477
28. Demidenko Z.N., and Blagosklonny M.V. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 64 (2004) 3653-3660
29. Christian B.A., et al. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol. 19 (2007) 573-578
30. Byrd J.C., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
31. Chen, R. et al. (2005) Flavopiridol induces apoptosis in chronic lymphocytic leukemia (CLL) cells through the transcriptional downregulation of anti-apoptotic proteins. Proc. Am. Assoc. Cancer Res. 46, Abs. 3266.
32. Aklilu M., et al. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann. Oncol. 14 (2003) 1270-1273
33. Morris D.G., et al. A Phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma (2006) 64374
34. Van Veldhuizen P.J., et al. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother. Pharmacol. 56 (2005) 39-45
35. Liu G., et al. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin. Cancer Res. 10 (2004) 924-928
36. Misra R.N., et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 47 (2004) 1719-1728
37. Heath E.I., et al. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest. New Drugs 26 (2008) 59-65
38. Raje N., et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. Blood 106 (2005) 1042-1047
39. MacCallum D.E., et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and downregulation of Mcl-1. Cancer Res. 65 (2005) 5399-5407
40. Benson C., et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 96 (2007) 29-37
41. Huang S., et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg. Med. Chem. Lett. 16 (2006) 3639-3641
42. Emanuel S., et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 65 (2005) 9038-9046
43. Seamon J.A., et al. Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol. Cancer Ther. 5 (2006) 2459-2467
44. Mendoza N., et al. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res. 63 (2003) 1020-1024
45. Biondi R.M., and Nebreda A.R. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem. J. 372 Pt 1 (2003) 1-13
46. Andrews M.J., et al. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chem. Biochem. 7 (2006) 1909-1915
47. Andrews M.J.I., et al. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org. Biomol. Chem. 2 (2004) 2341-2735
48. Canela, N. et al. (2006) Identification of an hexapeptide that binds to a surface pocket in cyclin A and inhibits the catalytic activity of the complex cyclin-dependent kinase 2-cyclin A. Vol. 281, pp. 35942-35953